SANTA FE, N.M., Aug. 16, 2011 /PRNewswire/ -- Sigma Labs, Inc. (OTCBB: SGLB) Sigma Labs, Inc. announced today that it received a fourth contract from Messier-Bugatti-Dowty (MBD) to apply Sigma Labs' In-Process Quality Assurance (IPQA) software to certain critical aspects of MBD's landing gear manufacturing. This recent contract from MBD's Canadian division follows three previous contracts from MBD's UK Division to further introduce our IPQA to specifically address MBD's next-generation manufacturing needs.
Mark Cola, President of Sigma Labs, states that "this development effort with MBD seeks to reduce MBD's manufacturing costs, introduce new quality assurance technology into their manufacturing processes, and help them maintain very high levels of quality and product safety." Vivek Dave, Vice President of Sigma Labs, states that "this contract will enable us to demonstrate important cost-savings aspects of our IPQA software to MBD, and to discuss future interactions and plans as they seek to introduce new and advanced manufacturing technology into their product lines."
About Sigma Labs, Inc.
Sigma Labs, Inc. comprises leading scientists and engineers from Los Alamos National Laboratory with over 75 years of combined industrial R&D experience and has become a developer of manufacturing and materials technologies and an important R&D provider to first-tier integrators, including Boeing, Honeywell, and Pratt & Whitney, as well as to commercial firms within the United States and internationally. Sigma Labs, Inc. currently has contracts with both the federal Government and private industry to develop technologies from their conception through the design, building, and testing of prototype systems. Sigma Labs, Inc. is aggressively designing and developing innovative sensing, software products, materials technologies and other unique manufacturing quality assurance solutions for the federal Government and our commercial clients. Visit Sigma Labs at www.sigmalabsinc.com.
This news release contains forward-looking statements that reflect Management's current views about future events and financial performance. Forward-looking statements often contain words such as "expects," "anticipates," "intends," "believes" or "will." Our forward-looking statements are subject to a number of risks and uncertainties that may cause actual results and events to differ materially from those projected in the forward-looking statements. Risks and uncertainties that could adversely affect us include, without limitation, the loss of major customers, our failure to obtain new contracts, our inability to patent products or processes, our infringement of patents held by others, our inability to finance our business and the other risks and uncertainties that are discussed in our most recent filings with the Securities and Exchange Commission, including our most recent annual report on Form 10-K and our Report on Form 8-K that was filed in connection with the transaction we recently completed with B6 Sigma. The forward-looking statements in this news release are made only as of the date of this news release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Sigma Labs, Inc.